Does Vitamin D Damage the Kidneys? Deficiency vs Toxicity Explained This question arises frequently—and understandably—because vitamin D is often discussed alongside calcium, kidney stones, and renal disease. The short answer is nuanced: Physiologic vitamin D replacement does not  cause kidney damage. In contrast, vitamin D deficiency  is increasingly recognized as a contributor to progressive renal injury. The confusion stems from conflating vitamin D toxicity —a rare, iatrogenic condition—with appropriate endocrine replacement  of a hormone the kidney both activates and depends upon. Vitamin D Deficiency: A Driver of Renal Injury When vitamin D signaling is inadequate, the kidney is affected through multiple well-described mechanisms: Up-regulation of the renin–angiotensin–aldosterone system (RAAS) Vitamin D normally suppresses renin expression. Deficiency promotes intraglomerular hypertension, accelerating nephron loss. Podocyte dysfunction and proteinuria Active vitamin D protects podocytes and the glomerular basement membrane. Low levels are associated with increased albuminuria. Fibrotic signaling Vitamin D inhibits TGF-β–mediated fibrosis. Deficiency permits unchecked interstitial scarring. Secondary hyperparathyroidism Rising PTH increases phosphate burden, vascular calcification, and renal metabolic stress. In this context, low vitamin D is not merely a marker of kidney disease—it is a mechanistic participant in its progression . When Vitamin D Can  Be Harmful: The Toxicity Scenario Reports of vitamin D–associated kidney injury almost universally involve toxicity , not replacement. Key features of true vitamin D toxicity include: Sustained hypercalcemia Very high dosing , typically far exceeding physiologic needs Prolonged exposure  without laboratory monitoring Often absent magnesium sufficiency , which normally regulates calcium flux In these rare cases, hypercalcemia can cause: Renal vasoconstriction Nephrocalcinosis Acute kidney injury This is a dose-related toxic effect , not a property of vitamin D itself. Importantly, these scenarios are exceptional  and do not  reflect standard clinical use. Replacement Is Not Toxicity A critical distinction must be made: Physiologic Vitamin D Replacement Vitamin D Toxicity Restores endocrine signaling Disrupts calcium balance Suppresses RAAS and PTH Causes sustained hypercalcemia Protective to podocytes Promotes nephrocalcinosis Supports renal health Can impair renal function When dosed appropriately and monitored, vitamin D replacement is renoprotective , not nephrotoxic. The Clinical Paradox Ironically, the patients most often denied vitamin D supplementation —those with chronic kidney disease—are frequently the ones who stand to benefit most from restoring normal vitamin D signaling. Avoiding correction of deficiency out of fear of toxicity risks allowing: Progressive proteinuria Accelerated eGFR decline Worsening secondary hyperparathyroidism All of which independently worsen renal outcomes. Bottom Line for Patients and Clinicians Vitamin D deficiency contributes to kidney damage Physiologic replacement does not harm the kidneys Toxicity is rare, preventable, and dose-dependent Monitoring calcium, PTH, and vitamin D levels eliminates risk The kidney is not merely a bystander in vitamin D metabolism—it is a central participant. Supporting that system appropriately is part of preserving renal health, not endangering it. References Li YC, Kong J, Wei M, Chen ZF, Liu SQ, Cao LP. 1,25-Dihydroxyvitamin D₃ is a negative endocrine regulator of the renin–angiotensin system. J Clin Invest.  2002;110(2):229–238. https://pubmed.ncbi.nlm.nih.gov/12122115/ Zhang Y, Kong J, Deb DK, Chang A, Li YC. Vitamin D receptor attenuates renal fibrosis by suppressing the renin–angiotensin system. J Am Soc Nephrol.  2010;21(6):966–973. https://pubmed.ncbi.nlm.nih.gov/20488955/ de Zeeuw D, Agarwal R, Amdahl M, et al. Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study). Lancet.  2010;376(9752):1543–1551. https://pubmed.ncbi.nlm.nih.gov/21055801/ Agarwal R, Acharya M, Tian J, et al. Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int.  2005;68(6):2823–2828. https://pubmed.ncbi.nlm.nih.gov/16316360/ Dusso AS, Brown AJ, Slatopolsky E. Vitamin D. Am J Physiol Renal Physiol.  2005;289(1):F8–F28. https://pubmed.ncbi.nlm.nih.gov/15951480/ Holick MF. Vitamin D deficiency. N Engl J Med.  2007;357(3):266–281. https://pubmed.ncbi.nlm.nih.gov/17634462/ Pilz S, Tomaschitz A, Friedl C, et al. Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant.  2011;26(11):3603–3611. https://pubmed.ncbi.nlm.nih.gov/21436313/ Ketteler M, Biggar PH, Liangos O, et al. Vitamin D analogues and survival in chronic kidney disease. Kidney Int.  2010;77(5):399–407. https://pubmed.ncbi.nlm.nih.gov/20054288/ Vieth R. Vitamin D toxicity, policy, and science. J Bone Miner Res.  2007;22(S2):V64–V68. https://pubmed.ncbi.nlm.nih.gov/18290718/ Marins TA, Galvão TF, Korkes F, Malerbi DA, Ganc AJ. Vitamin D intoxication: case report. Clin Nephrol.  2014;82(1):49–53. https://pubmed.ncbi.nlm.nih.gov/24962410/ The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Fatigue, Weight Gain, Feeling Cold — and “Normal” Tests That Don’t Explain How You Feel Could It Be Your Thyroid? Symptoms Doctors Often Miss “I’m exhausted all the time. I’m gaining weight even though I’m eating the same. I feel cold when everyone else is comfortable. My hair is thinning. My thinking feels slower. But my doctor says my thyroid labs are normal.” If this sounds familiar, you are not alone — and you are not imagining things. This scenario is one of the most common frustrations in modern clinical practice. Patients experience classic hypothyroid symptoms , yet are reassured or dismissed because a single laboratory value — usually TSH — falls within a population reference range¹. This article explains why thyroid problems are so often missed , what standard testing fails to capture, and how temperature, genetics, diet, stress, autoimmunity, and cellular metabolism all influence how thyroid dysfunction actually feels in real life. The Thyroid Is a Metabolic Regulator — Not a Checkbox The thyroid gland influences nearly every system in the body. Thyroid hormones regulate basal metabolic rate, thermogenesis, mitochondrial energy production, lipid and glucose metabolism, gastrointestinal motility, neurocognitive speed, mood, and tissue turnover². When thyroid signaling is impaired, the body shifts into a low-energy, low-output state , producing fatigue, cold intolerance, weight gain, constipation, cognitive slowing, and depressive symptoms³. The central problem in modern care is not that hypothyroidism is ignored — it is that it is defined too narrowly . Why TSH Alone Is an Incomplete Answer Why Normal Thyroid Labs Miss Tissue-Level Hypothyroidism TSH reflects pituitary signaling, not tissue-level thyroid effect⁴. A “normal” TSH presumes intact hypothalamic-pituitary signaling, adequate hormone synthesis, efficient T4-to-T3 conversion, and normal cellular uptake and receptor sensitivity. Breakdown at any of these steps can result in hypothyroid symptoms despite normal reference-range labs ⁵. Numerous studies demonstrate discordance between serum TSH and peripheral thyroid hormone action⁶. Low Body Temperature: A Forgotten Clinical Clue Low Body Temperature: A Hidden Sign of Hypothyroidism Thyroid hormones are primary drivers of metabolic heat production. Reduced thyroid signaling is associated with lower basal body temperature , a finding described in both historical and modern physiologic studies⁷. Patients with hypothyroidism commonly demonstrate: Morning temperatures below ~97.8°F (36.6°C) Increased temperature variability Impaired thermogenic response to stress or illness⁸ NOTE: Oral Temperatures are NEVER NORMAL if they are in the 96's!!!! Serial temperature tracking provides a functional measure of metabolic output , complementing biochemical testing rather than replacing it⁹. Why Symptoms Persist When Tests Look “Normal” Thyroid dysfunction is not monolithic. Multiple pathophysiologic pathways can produce hypothyroid symptoms without overt laboratory abnormalities¹⁰. Hypothyroidism Is Not One Condition Autoimmune Hypothyroidism (Hashimoto’s Disease) Types of Thyroid Disease: Hypothyroid, Autoimmune, and More Hashimoto’s thyroiditis is the most common cause of hypothyroidism in iodine-sufficient regions¹¹. Thyroid peroxidase and thyroglobulin antibodies often precede biochemical hypothyroidism by years, during which patients may already be symptomatic¹². Autoimmune thyroid disease frequently progresses in a non-linear fashion , with fluctuating hormone production and periods of apparent biochemical normalcy¹³. Functional Hypothyroidism (Impaired Conversion or Utilization) Functional vs Autoimmune Hypothyroidism: Why Symptoms Differ Peripheral conversion of T4 to active T3 is mediated by deiodinase enzymes. Inflammation, illness, caloric restriction, insulin resistance, and glucocorticoid excess can reduce T3 availability despite normal T4 levels¹⁴. Reduced tissue responsiveness to thyroid hormone has been demonstrated even in patients with “adequate” serum concentrations¹⁵. Epigenetic and Stress-Mediated Thyroid Suppression Stress, infection, trauma, and chronic illness can suppress thyroid hormone signaling via epigenetic mechanisms affecting deiodinase expression and receptor sensitivity¹⁶. This adaptive response becomes maladaptive when prolonged, producing persistent hypothyroid symptoms without classic lab abnormalities¹⁷. Genetic Influences on Thyroid Disease Genetic predisposition plays a substantial role in thyroid dysfunction. Polymorphisms in genes regulating immune tolerance (HLA), thyroid hormone synthesis, deiodinase activity (notably DIO2 ), and thyroid hormone receptors influence symptom severity and treatment response¹⁸–²⁰. These variants do not cause disease in isolation, but lower the physiologic threshold  at which environmental, dietary, or inflammatory stressors provoke symptoms. This explains familial clustering of thyroid disorders and variable symptom burden among patients with similar laboratory values²¹. Diet and Thyroid Function: An Overlooked Interaction Soy and thyroid physiology Soy isoflavones inhibit thyroid peroxidase activity and interfere with iodine utilization²². In iodine-deficient or autoimmune-prone individuals, soy intake has been shown to impair thyroid hormone synthesis and worsen hypothyroid symptoms²³. Soy also reduces intestinal absorption of levothyroxine, necessitating higher doses in some patients²⁴. Other dietary contributors include: Severe caloric restriction²⁵ Excessive raw cruciferous vegetable intake²⁶ Iron and selenium deficiency²⁷ Iodine imbalance²⁸ Diet-induced thyroid suppression is often reversible when recognized. Why Patients Feel Dismissed — and Why That Matters Patients with persistent symptoms and “normal labs” are frequently misattributed to aging, mood disorders, or lifestyle failure. This delays diagnosis and worsens quality of life²⁹. Thyroid disease exists on a spectrum , and early functional impairment is the most commonly overlooked stage³⁰. A More Complete Thyroid Evaluation Meaningful thyroid assessment integrates symptoms, temperature patterns, comprehensive thyroid testing, autoimmune markers, metabolic context, and environmental factors³¹. The essential question remains: Does the physiology match how the patient feels? Bottom Line A normal TSH does not rule out clinically meaningful thyroid dysfunction. When evaluation expands beyond a single laboratory value, many patients finally receive explanations consistent with their lived experience. Feeling unwell is not a failure. It is data. Ready to Take the Next Step? If you’ve been told your thyroid is “normal” but you still feel unwell, a deeper evaluation may be appropriate. At Stages of Life Medical Institute , we assess thyroid health in the context of symptoms, physiology, metabolism, and real-world function , not just reference ranges. 👉 Schedule a comprehensive thyroid evaluation today References Surks MI, et al. Subclinical thyroid disease.  JAMA. 2004. https://pubmed.ncbi.nlm.nih.gov/15315978/ Mullur R, et al. Thyroid hormone regulation of metabolism.  Physiol Rev. 2014. https://pubmed.ncbi.nlm.nih.gov/24384871/ McAninch EA, Bianco AC. The history and future of thyroid hormone replacement.  Ann Intern Med. 2016. https://pubmed.ncbi.nlm.nih.gov/27088410/ Brabant G, et al. Pituitary–thyroid feedback.  Eur J Endocrinol. 2015. https://pubmed.ncbi.nlm.nih.gov/25869228/ Hoermann R, et al. Homeostatic control of thyroid function.  Front Endocrinol. 2015. https://pubmed.ncbi.nlm.nih.gov/26425644/ Peterson SJ, et al. Serum TSH and peripheral thyroid hormone action.  J Clin Endocrinol Metab. 2018. https://pubmed.ncbi.nlm.nih.gov/29546328/ Barnes BO. Basal temperature and thyroid function.  JAMA. 1972. https://pubmed.ncbi.nlm.nih.gov/5010288/ Alkemade A, et al. Thermogenesis and thyroid hormone.  Endocr Rev. 2005. https://pubmed.ncbi.nlm.nih.gov/15901650/ McCarty MF. Functional markers of hypothyroidism.  Med Hypotheses. 2000. https://pubmed.ncbi.nlm.nih.gov/10917488/ Bianco AC. Tissue hypothyroidism.  Endocr Rev. 2019. https://pubmed.ncbi.nlm.nih.gov/30629182/ Vanderpump MPJ. Epidemiology of autoimmune thyroid disease.  Clin Endocrinol. 2011. https://pubmed.ncbi.nlm.nih.gov/21671984/ Tunbridge WMG, et al. Natural history of autoimmune thyroiditis.  Clin Endocrinol. 1977. https://pubmed.ncbi.nlm.nih.gov/598014/ Weetman AP. Autoimmune thyroid disease.  Endocr Rev. 2000. https://pubmed.ncbi.nlm.nih.gov/10857522/ Peeters RP. Non-thyroidal illness and thyroid hormone metabolism.  Best Pract Res Clin Endocrinol Metab. 2001. https://pubmed.ncbi.nlm.nih.gov/11520477/ Escobar-Morreale HF, et al. Tissue hypothyroidism despite normal serum levels.  J Clin Endocrinol Metab. 2005. https://pubmed.ncbi.nlm.nih.gov/15687338/ Fliers E, et al. Stress and thyroid function.  Nat Rev Endocrinol. 2014. https://pubmed.ncbi.nlm.nih.gov/24663233/ Boelen A, et al. Epigenetic regulation of thyroid hormone metabolism.  Endocr Rev. 2011. https://pubmed.ncbi.nlm.nih.gov/21490178/ Panicker V, et al. DIO2 polymorphisms and thyroid hormone action.  J Clin Endocrinol Metab. 2009. https://pubmed.ncbi.nlm.nih.gov/19116303/ Taylor PN, et al. Genetic influences on thyroid function.  Nat Rev Endocrinol. 2018. https://pubmed.ncbi.nlm.nih.gov/29511369/ Canaris GJ, et al. The Colorado thyroid disease prevalence study.  Arch Intern Med. 2000. https://pubmed.ncbi.nlm.nih.gov/11146715/ Hansen PS, et al. Genetic and environmental factors in thyroid disease.  J Clin Endocrinol Metab. 2004. https://pubmed.ncbi.nlm.nih.gov/15126517/ Messina M, Redmond G. Effects of soy protein and isoflavones on thyroid function.  Thyroid. 2006. https://pubmed.ncbi.nlm.nih.gov/16571087/ Doerge DR, Chang HC. Isoflavones and thyroid enzyme inhibition.  Environ Health Perspect. 2002. https://pubmed.ncbi.nlm.nih.gov/11940448/ Bell DS, Ovalle F. Soy protein interference with levothyroxine absorption.  Endocr Pract. 2001. https://pubmed.ncbi.nlm.nih.gov/11716045/ Wartofsky L, Burman KD. Alterations in thyroid function during starvation.  Endocr Rev. 1982. https://pubmed.ncbi.nlm.nih.gov/6280934/ Chandra AK, et al. Goitrogenic potential of cruciferous vegetables.  Nutrition. 2014. https://pubmed.ncbi.nlm.nih.gov/24613616/ Zimmermann MB. Iodine and selenium deficiency.  Endocr Rev. 2009. https://pubmed.ncbi.nlm.nih.gov/19589949/ Leung AM, et al. Iodine excess and thyroid dysfunction.  Endocr Rev. 2012. https://pubmed.ncbi.nlm.nih.gov/22565024/ Saravanan P, et al. Psychological well-being in treated hypothyroidism.  Clin Endocrinol. 2002. https://pubmed.ncbi.nlm.nih.gov/12354155/ Hoermann R, Midgley JEM. Rethinking thyroid disease classification.  Eur J Endocrinol. 2012. https://pubmed.ncbi.nlm.nih.gov/22865594/ Jonklaas J, et al. Guidelines for hypothyroidism evaluation and management.  Thyroid. 2014. https://pubmed.ncbi.nlm.nih.gov/25266247/ The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Microplastics Exposure Pathways in Humans For decades, plastic was regarded as biologically inert—an engineering success with little relevance to human physiology. That assumption is now being actively challenged. Microplastics and nanoplastics , defined as plastic fragments smaller than 5 mm and often far smaller than a human cell, have now been identified in human blood, lung tissue, stool, placenta, breast milk, and atherosclerotic plaques ¹⁻⁴. Microplastics and human health: The medical implications are no longer speculative. They are measurable, reproducible, and increasingly relevant to everyday clinical practice. What Are Microplastics—and Why Size Matters Microplastics originate from the degradation of larger plastic products (bottles, packaging, synthetic clothing, tire wear) as well as from intentionally manufactured particles used in industry and consumer goods. As particle size decreases, biological relevance increases: >150 µm : typically excreted 10–150 µm : may cross intestinal or pulmonary epithelium <1 µm (nanoplastics) : capable of cellular uptake and systemic distribution⁵ At this scale, plastics cease to behave as inert debris and begin functioning as biologically active particulates . Routes of Human Exposure Human exposure is now continuous and unavoidable: Ingestion : bottled water, seafood, salt, packaged foods⁶⁻⁸ Inhalation : indoor dust, synthetic fibers, urban air pollution⁹ Dermal contact : limited absorption, but relevant for chemical additives Once internalized, microplastics may persist in tissues for prolonged periods, particularly when embedded in inflammatory or lipid-rich environments. Potential Health Effects of Microplastics Gastrointestinal and Metabolic Effects The gastrointestinal tract represents the primary interface between microplastics and human physiology. Experimental and observational studies demonstrate: Disruption of intestinal epithelial tight junctions Increased intestinal permeability Alteration of gut microbiota composition Local immune activation and oxidative stress ¹⁰⁻¹² These mechanisms intersect directly with conditions routinely managed in clinical practice, including insulin resistance, metabolic syndrome, inflammatory bowel disease, and MASLD. Endocrine and Hormonal Disruption Microplastics act not only as particles but as chemical vectors . Many carry or adsorb endocrine-active compounds such as bisphenols, phthalates, and persistent organic pollutants¹³. Documented and proposed effects include: Interference with estrogen, androgen, and thyroid hormone signaling Disruption of nuclear receptor activity Epigenetic modification of gene expression¹⁴⁻¹⁶ From a clinical perspective, these findings raise concerns regarding fertility, pubertal development, thyroid disease, and hormonally mediated cancers . Cardiovascular and Inflammatory Risk Recent human data have identified microplastics within atherosclerotic plaques , a finding associated with increased local inflammation and adverse cardiovascular outcomes¹⁷. While causality has not yet been established, the pattern mirrors prior environmental exposures now recognized as cardiovascular risk modifiers: chronic inflammation, oxidative stress, and endothelial dysfunction. Neuroimmune and Developmental Considerations Animal models and early human evidence suggest that nanoplastics may cross both the blood–brain barrier  and the placental barrier ¹⁸⁻²⁰. This raises clinically relevant—but as yet unanswered—questions regarding: Neuroinflammation and microglial activation Prenatal immune programming Long-term neurodevelopmental effects Medicine has encountered this trajectory before. Lead, asbestos, and tobacco followed a similar arc: widespread exposure preceded mechanistic clarity. Microplastics and human health. Practical Risk Reduction: What Patients Can Do Now Ways to Reduce Microplastic Exposure While definitive clinical guidelines are still evolving, several low-risk, evidence-aligned strategies  are reasonable: Prefer glass or stainless steel for food and beverages Avoid heating food in plastic containers Use filtered drinking water when feasible Reduce consumption of ultra-processed and heavily packaged foods Support metabolic and inflammatory resilience through nutrition, exercise, sleep, and stress management The goal is risk reduction , not elimination—an unrealistic expectation in modern environments. A Measured Medical Perspective Microplastics should not be framed as a source of alarm, nor dismissed as irrelevant. They represent a novel, cumulative exposure  interacting with inflammation, metabolism, endocrine signaling, and immune regulation. Medicine is still defining the contours of this risk. However, history suggests that early biological signals deserve attention , particularly when exposure is lifelong and ubiquitous. Environmental exposures intersect with inflammation, metabolism, and hormonal balance. If you are concerned about long-term health resilience, a personalized medical evaluation can help identify modifiable risk factors . 👉 Schedule a consultation with Stages of Life Medical Institute. REFERENCES Leslie HA, van Velzen MJM, Brandsma SH, Vethaak AD, Garcia-Vallejo JJ, Lamoree MH. Discovery and quantification of plastic particle pollution in human blood. Environ Int.  2022;163:107199. https://pubmed.ncbi.nlm.nih.gov/35056410/ Ragusa A, Svelato A, Santacroce C, et al. Plasticenta: First evidence of microplastics in human placenta. Environ Int.  2021;146:106274. https://pubmed.ncbi.nlm.nih.gov/33395930/ Schwabl P, Köppel S, Königshofer P, et al. Detection of various microplastics in human stool: A prospective case series. Ann Intern Med.  2019;171(7):453-457. https://pubmed.ncbi.nlm.nih.gov/31476765/ Marfella R, Prattichizzo F, Sardu C, et al. Microplastics and nanoplastics in atherosclerotic plaques and cardiovascular events. N Engl J Med.  2024;390(10):900-910. https://pubmed.ncbi.nlm.nih.gov/38388430/ Wright SL, Kelly FJ. Plastic and human health: A micro issue? Environ Sci Technol.  2017;51(12):6634-6647. https://pubmed.ncbi.nlm.nih.gov/29161219/ Cox KD, Covernton GA, Davies HL, Dower JF, Juanes F, Dudas SE. Human consumption of microplastics. Environ Sci Technol.  2019;53(12):7068-7074. https://pubmed.ncbi.nlm.nih.gov/31151256/ Kosuth M, Mason SA, Wattenberg EV. Anthropogenic contamination of tap water, beer, and sea salt. Front Chem.  2018;6:407. https://pubmed.ncbi.nlm.nih.gov/30062106/ Karami A, Golieskardi A, Choo CK, Larat V, Galloway TS, Salamatinia B. The presence of microplastics in commercial salts from different countries. Sci Rep.  2017;7:46173. https://pubmed.ncbi.nlm.nih.gov/28724929/ Vianello A, Jensen RL, Liu L, Vollertsen J. Simulating human exposure to indoor airborne microplastics using a breathing thermal manikin. PLoS One.  2019;14(1):e0211020. https://pubmed.ncbi.nlm.nih.gov/30668565/ Jin Y, Lu L, Tu W, Luo T, Fu Z. Impacts of polystyrene microplastic on the gut barrier, microbiota, and metabolism of mice. Chemosphere.  2019;237:124433. https://pubmed.ncbi.nlm.nih.gov/30844682/ Lu L, Wan Z, Luo T, Fu Z, Jin Y. Polystyrene microplastics induce gut microbiota dysbiosis and hepatic lipid metabolism disorder in mice. Sci Total Environ.  2018;631-632:449-458. https://pubmed.ncbi.nlm.nih.gov/29609994/ Hirt N, Body-Malapel M. Immunotoxicity and intestinal effects of nano- and microplastics. Part Fibre Toxicol.  2020;17(1):57. https://pubmed.ncbi.nlm.nih.gov/34391635/ Rochman CM, Hentschel BT, Teh SJ. Long-term sorption of metals is similar among plastic types: Implications for plastic debris in aquatic environments. Sci Rep.  2013;3:3263. https://pubmed.ncbi.nlm.nih.gov/23862916/ Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, et al. Endocrine-disrupting chemicals: An Endocrine Society scientific statement. Endocr Rev.  2009;30(4):293-342. https://pubmed.ncbi.nlm.nih.gov/19416694/ Trasande L, Zoeller RT, Hass U, et al. Estimating burden and disease costs of exposure to endocrine-disrupting chemicals in the European Union. Lancet Diabetes Endocrinol.  2015;3(12):996-1002. https://pubmed.ncbi.nlm.nih.gov/32085892/ Li J, Yang D, Li L, Jabeen K, Shi H. Microplastics in commercial bivalves from China. J Hazard Mater.  2020;399:123999. https://pubmed.ncbi.nlm.nih.gov/32086005/ Marfella R, Sardu C, Prattichizzo F, et al. Microplastic accumulation and cardiovascular outcomes. N Engl J Med.  2024;390(10):900-910. https://pubmed.ncbi.nlm.nih.gov/38388430/ Prüst M, Meijer J, Westerink RHS. The plastic brain: Neurotoxicity of micro- and nanoplastics. Environ Health Perspect.  2020;128(12):123001. https://pubmed.ncbi.nlm.nih.gov/32167873/ Fournier SB, D’Errico JN, Adler DS, et al. Nanopolystyrene translocation and fetal deposition after acute lung exposure during pregnancy. Toxicol Sci.  2020;175(1):56-69. https://pubmed.ncbi.nlm.nih.gov/31912157/ Wick P, Malek A, Manser P, et al. Barrier capacity of human placenta for nanosized materials. Environ Health Perspect.  2010;118(3):432-436. https://pubmed.ncbi.nlm.nih.gov/20826301/ The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Most patients encounter Medicare Advantage plans through attractive headlines: low or zero premiums , extra benefits , simplified coverage . On the surface, the appeal is understandable. For many healthy individuals, these plans function adequately—sometimes even well. The problems arise later, quietly, and often unexpectedly—when care becomes complex, diagnoses uncertain, or treatment non-standard. That is when patients discover that Medicare Advantage is not simply a different way of paying for care. It is a different system of control. When Care Is Denied Without a Medical Conversation Medicare Advantage Claim Denied – When Insurance Controls Care For most patients, denial does not arrive as a debate. It arrives as paperwork. A form. A letter. A stamp. DENIED. No physician discussion. No bedside reasoning. No nuanced assessment of risks and benefits. Just an administrative determination—often made by an insurer-employed reviewer who has never met the patient. This is not an edge case. It is a structural feature. Original Medicare vs. Medicare Advantage: A Structural Difference, Not a Branding One Medicare Advantage Network Restrictions Explained | Stages of Life Medical Institute Original Medicare (Parts A and B) is a public insurance framework . Coverage decisions are largely standardized, physician-directed, and broadly portable. Patients may choose their doctors. Physicians determine medical necessity. Medicare Advantage, by contrast, is private insurance operating under a government contract . The plan—not the patient, and often not the physician—controls access through: Restricted provider networks Prior authorization requirements Step therapy mandates Referral gatekeeping Coverage reinterpretation over time These tools are collectively called utilization management . They are not inherently unethical. But they shift decision-making authority  away from the clinical encounter and into administrative processes. Why These Restrictions Often Appear Late Many Medicare Advantage plans perform acceptably when patients are: Relatively healthy Seeing few specialists Managing routine or well-defined conditions Trouble emerges when patients develop: Multisystem illness Chronic pain syndromes Neurologic or cognitive decline Endocrine or metabolic complexity Conditions requiring diagnostic persistence rather than procedural shortcuts At precisely the moment when medical judgment matters most , the system introduces friction. The Physician’s View From Inside the System From the clinician’s side, this friction is unmistakable. Time once spent diagnosing and treating is redirected toward: Appeals Documentation justification Repeated resubmissions Peer-to-peer calls that are rarely peer-level in substance None of this improves care. It delays it. And delay, in medicine, is rarely neutral. You can expect to pay for the prior authorization process directly, as a fee, through additional office visits where the patient exchanges their time in the medical practice while the professionals fill out the 'forms,' or you simply pay for the services 'out of pocket.' The Cost Illusion Medicare Advantage plans often advertise low or zero monthly premiums. That savings is real—but incomplete. Costs frequently reappear as: Copay accumulation Coinsurance for advanced imaging or specialty care Out-of-network charges when restricted networks fail Deferred or foregone care due to administrative burden Inferior medications, medication delays The financial model works by reducing utilization , not by increasing efficiency. This Is Not About Villains It is important to be precise. This is not a condemnation of every Medicare Advantage plan, nor an accusation of malice. Many clinicians working within these systems do their best under difficult constraints. But systems shape behavior. And this system is designed to say “no” quietly, upstream, and often invisibly . The money that you think you are saving has the very likely possibility of costing you much more if you need higher quality than 'basic,' if you need specialized care rather than least costly, or if you need care that is more than the minimum contract expectations. In short, Advantage Plans bury you in denials, delays and prior authorizations. Who Should Think Carefully Before Enrolling Medicare Advantage may be reasonable for: Individuals with stable, uncomplicated medical needs Those comfortable remaining within narrow provider networks It deserves caution for: Patients with chronic pain or evolving diagnoses Those requiring diagnostic persistence rather than protocol-driven care Individuals who value physician autonomy and broad access Patients who anticipate increasing medical complexity with age Bottom Line Medicare Advantage is not merely an alternative payment structure. It is a reallocation of authority —from patients and physicians to insurers and administrators. The insurance carrier takes money right off of the top to "manage" your care. This most frequently means stearing you in a direction that reduces costs to them and thereby gives you a diminished medical 'experience.' The red DENIED  stamp does not appear randomly. It is the visible endpoint of a system designed to control care by controlling access. Understanding that distinction before  enrollment matters far more than understanding premiums. Call to Action If you are navigating Medicare decisions—or struggling to obtain appropriate care under an existing plan—a physician-led review can clarify options, risks, and next steps. 🩺 Become a Patient   Stages of Life Medical Institute (Care guided by diagnosis first—not paperwork.) Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

A Physician’s Framework for Uncovering Metabolic, Endocrine, Immune, and Autonomic Causes of Chronic Low Energy Feeling tired is common. Staying tired is not normal. Persistent fatigue—fatigue that lingers for months, resists rest, and quietly erodes quality of life—is one of the most frequent yet least satisfactorily addressed complaints in modern medicine. Too often, patients are reassured, prescribed stimulants or antidepressants, or told their labs are “normal,” despite ongoing symptoms. From a physician’s perspective, chronic fatigue is rarely a single-system problem. It is usually a signal of physiologic imbalance , often involving multiple overlapping domains: metabolic, endocrine, immune, neurologic, sleep-related, and autonomic. This article reframes fatigue not as a symptom to suppress, but as a diagnostic invitation . Why Persistent Fatigue Is Commonly Missed Modern clinical workflows favor speed and binary lab interpretation. Many of the conditions that drive chronic fatigue: Exist in subclinical ranges Affect hormone signaling , not just hormone levels Involve circadian, autonomic, or mitochondrial dysfunction Are invisible to standard screening panels As a result, patients are frequently told: “Everything looks normal.” Yet physiology does not operate on reference ranges—it operates on function . A Multisystem Differential Diagnosis of Persistent Fatigue Multisystem Causes of Persistent Fatigue | Metabolic, Endocrine, Immune Factors 1. Metabolic Dysfunction (Often Before Diabetes) Fatigue is one of the earliest manifestations of impaired energy metabolism. Common overlooked contributors include: Insulin resistance without hyperglycemia Reactive hypoglycemia Impaired metabolic flexibility Mitochondrial inefficiency and reduced ATP production Patients may report: Energy crashes after meals Brain fog Dependence on caffeine Weight gain despite unchanged intake Standard fasting glucose often fails to detect these patterns. Dynamic markers and insulin indices are far more revealing.¹² 2. Endocrine Disorders Beyond “Normal Labs” Endocrine and Metabolic Drivers of Fatigue | Hormones, Insulin, Mitochondria Endocrine fatigue is frequently missed because clinicians rely on isolated values rather than physiologic context . Key contributors include: Thyroid Dysfunction Central (secondary) hypothyroidism Impaired T4 → T3 conversion Thyroid hormone resistance Autoimmune thyroid disease with “normal” TSH³⁴ Adrenal and Cortisol Dysregulation Flattened diurnal cortisol rhythm Elevated evening cortisol Inadequate stress recovery Sex Hormone & Growth Hormone Decline Low bioavailable testosterone or estradiol Elevated SHBG masking deficiency Age-related IGF-1 decline amplifying fatigue and sarcopenia⁵ 3. Sleep and Circadian Disorders (Even Without Apnea) Sleep quantity does not equal sleep quality. Overlooked causes include: Upper airway resistance syndrome (UARS) Sleep fragmentation Circadian misalignment Reduced slow-wave or REM sleep Patients often say: “I sleep, but I never feel restored.” These disorders disrupt mitochondrial repair, hormone release, and autonomic balance—fueling daytime exhaustion.⁶ 4. Immune and Inflammatory Fatigue Low-grade inflammation is profoundly fatiguing. Potential drivers: Chronic cytokine elevation Autoimmune disease (often preclinical) Post-viral fatigue syndromes Mast cell activation disorders Inflammation alters neurotransmission, mitochondrial output, and cortisol signaling, creating a persistent “sickness behavior” state.⁷⁸ 5. Autonomic and Neurologic Contributors Dysautonomia is increasingly recognized—but still underdiagnosed. Features may include: Orthostatic intolerance Postural tachycardia Exercise intolerance Temperature dysregulation Patients often appear “normal” at rest yet experience profound fatigue with minimal exertion.⁹ 6. Medication-Induced Fatigue (Often Overlooked) Common offenders include: Statins SSRIs and SNRIs Beta blockers Antihistamines Proton pump inhibitors Even when clinically indicated, these medications may impair mitochondrial function, nutrient absorption, or autonomic tone—contributing to fatigue.¹⁰ A Clinical Evaluation Framework Diagnostic Evaluation of Chronic Fatigue | Clinical Pathway Beyond Routine Labs A meaningful evaluation of chronic fatigue should assess overlooked causes of persistent fatigue: Metabolic efficiency Hormone signaling and circadian patterns Inflammatory and immune markers Nutrient sufficiency Autonomic balance Sleep architecture The goal is not to label fatigue—but to explain it . Why This Matters Fatigue is not merely inconvenient. Left uninvestigated, it is often a precursor  to: Cardiometabolic disease Neurocognitive decline Mood disorders Accelerated aging Reduced resilience to illness When properly evaluated, fatigue becomes one of the most informative symptoms in medicine. A Physician-Led Perspective At Stages of Life Medical Institute , persistent fatigue is approached as a diagnostic problem , not a lifestyle failure. Care begins with careful listening, comprehensive evaluation, and an appreciation for the interconnected nature of human physiology. If you’ve been told your labs are “normal” but you don’t feel normal, further evaluation may be warranted. REFERENCES DeFronzo RA.  Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. Diabetologia.  2010;53(7):1270–1287. https://pubmed.ncbi.nlm.nih.gov/20361178/ Kraft JR.  Detection of diabetes mellitus in situ (occult diabetes). Lab Med.  1975;6(2):10–22. https://pubmed.ncbi.nlm.nih.gov/1124128/ Fliers E, Alkemade A, Wiersinga WM, Swaab DF.  Hypothalamic thyroid hormone feedback in health and disease. Prog Brain Res.  2006;153:189–207. https://pubmed.ncbi.nlm.nih.gov/16876578/ Wiersinga WM.  Paradigm shifts in thyroid hormone replacement therapies for hypothyroidism. Nat Rev Endocrinol.  2014;10(3):164–174. https://pubmed.ncbi.nlm.nih.gov/24419309/ Veldhuis JD, Iranmanesh A, Ho KK, Waters MJ, Johnson ML, Lizarralde G.  Dual defects in pulsatile growth hormone secretion and clearance subserve the hyposomatotropism of obesity in man. J Clin Endocrinol Metab.  1991;72(1):51–59. https://pubmed.ncbi.nlm.nih.gov/1986035/ Walker MP.  The role of sleep in cognition and emotion. Ann N Y Acad Sci.  2009;1156:168–197. https://pubmed.ncbi.nlm.nih.gov/19338508/ Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW.  From inflammation to sickness and depression: when the immune system subjugates the brain. Nat Rev Neurosci.  2008;9(1):46–56. https://pubmed.ncbi.nlm.nih.gov/18073775/ Komaroff AL.  Advances in understanding the pathophysiology of chronic fatigue syndrome. JAMA.  2019;322(6):499–500. https://pubmed.ncbi.nlm.nih.gov/31454044/ Freeman R, Wieling W, Axelrod FB, et al.  Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res.  2011;21(2):69–72. https://pubmed.ncbi.nlm.nih.gov/21431947/ Golomb BA, Evans MA.  Statin adverse effects: a review of the literature and evidence for a mitochondrial mechanism. Am J Cardiovasc Drugs.  2008;8(6):373–418. https://pubmed.ncbi.nlm.nih.gov/19159124/ The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Introduction: Dementia Is a Diagnosis of Exclusion Is It Dementia or Something Else? Conditions That Mimic Dementia Few words in medicine carry as much emotional weight as dementia . For patients and families, it often implies permanence, inevitability, and progressive loss. Clinically, that assumption is incomplete. One of the most important principles in cognitive medicine is this: Not all cognitive decline is dementia. A wide range of medical, psychiatric, metabolic, and medication-related conditions can produce symptoms that closely resemble neurodegenerative disease. Many are treatable , some are reversible , and nearly all require careful evaluation before a life-altering diagnosis is assigned. Delirium: The Most Common and Most Missed Mimic Common Reversible Causes of Dementia-Like Symptoms Delirium is an acute or subacute disturbance of attention and cognition , typically developing over hours to days and fluctuating throughout the day¹. Hallmark Features Sudden onset Fluctuating mental status Impaired attention Altered level of consciousness Disorganized thinking Common precipitants include infection, dehydration, metabolic abnormalities, medication toxicity, withdrawal states, and acute illness². Delirium frequently coexists with underlying cognitive vulnerability and may unmask previously compensated impairment³. Key distinction: Dementia is chronic and progressive . Delirium is acute and often reversible. Medication Effects and Polypharmacy Medication-related cognitive impairment is among the most frequent and correctable  causes of dementia-like symptoms. Common Offending Drug Classes Anticholinergics (e.g., diphenhydramine, oxybutynin) Benzodiazepines Z-hypnotics Opioids Antipsychotics Certain antidepressants Corticosteroids Anticholinergic burden has been strongly associated with confusion, memory impairment, falls, and increased dementia risk⁴⁵. Because medication effects often develop insidiously, they are frequently mistaken for early Alzheimer’s disease unless a deliberate medication review is performed. A Z-hypnotic  is a class of non-benzodiazepine sedative–hypnotic medications  primarily prescribed for insomnia . They are called “Z-drugs” because most of their names begin with the letter Z . Common Z-Hypnotics Zolpidem  (Ambien®, Ambien CR®) Zaleplon  (Sonata®) Eszopiclone  (Lunesta®) How They Work Z-hypnotics act on the GABA-A receptor complex , selectively binding to the α1 subunit. This promotes sedation and sleep initiation, with less anxiolytic or muscle-relaxant effect than traditional benzodiazepines. They were initially marketed as safer alternatives to benzodiazepines, but this distinction has proven incomplete. Why They Matter Clinically Although commonly prescribed, Z-hypnotics are not benign , particularly in older adults. Documented adverse effects include: Memory impairment and anterograde amnesia Confusion and delirium Impaired balance and increased fall risk Parasomnias (sleep-walking, sleep-driving, eating during sleep) Next-day cognitive “hangover” effects In geriatric patients, Z-hypnotics are associated with worsened cognitive performance and increased risk of delirium , making them important contributors to dementia-like presentations. For this reason, they are listed in the Beers Criteria  as potentially inappropriate medications for older adults. Depression and “Pseudodementia” Major depressive disorder can present with prominent cognitive symptoms, including impaired concentration, memory complaints, slowed processing, and executive dysfunction. This presentation, historically termed depressive pseudodementia , differs from neurodegenerative dementia in important ways⁶⁷: Patients emphasize cognitive deficits Performance varies with effort and encouragement Mood symptoms precede cognitive decline Cognition often improves with effective treatment Depression and dementia may coexist, but untreated mood disorders remain a leading reversible contributor to cognitive impairment. Metabolic and Endocrine Disorders Thyroid Disease Both hypothyroidism and hyperthyroidism can impair cognition. Hypothyroidism is classically associated with slowed thinking, memory difficulty, and depressive features⁸. Vitamin Deficiencies Vitamin B12 deficiency  may cause memory loss, executive dysfunction, gait disturbance, and neuropathy⁹ Folate deficiency  contributes to impaired cognition Thiamine deficiency  may lead to Wernicke–Korsakoff spectrum disorders Electrolyte and Systemic Abnormalities Hyponatremia, hypercalcemia, hypoglycemia, hepatic encephalopathy, and uremia can all produce cognitive syndromes resembling dementia¹⁰. Sleep Disorders and Cognitive Performance Obstructive Sleep Apnea (OSA) Sleep apnea is an underrecognized contributor to cognitive decline. Chronic intermittent hypoxia and sleep fragmentation impair attention, memory, and executive function¹¹. Common features include: Memory complaints Daytime fatigue Mood changes Reduced processing speed Treatment with CPAP has been shown to improve cognitive performance, particularly when initiated early¹². Normal Pressure Hydrocephalus: A Reversible Cause Not to Miss Normal pressure hydrocephalus (NPH) remains one of the most important — and most overlooked — reversible causes of dementia-like symptoms. The classic triad includes¹³: Gait disturbance (often earliest) Cognitive impairment Urinary urgency or incontinence Neuroimaging typically shows ventriculomegaly disproportionate to cortical atrophy. Selected patients may benefit substantially from cerebrospinal fluid diversion. Infections and Inflammatory Conditions Certain chronic or subacute infections and inflammatory disorders may present primarily with cognitive decline, including: HIV-associated neurocognitive disorder Neurosyphilis Lyme disease Autoimmune or paraneoplastic encephalitis¹⁴ Though less common, these etiologies are essential to recognize because targeted treatment may significantly alter outcome. Sensory Impairment and Apparent Cognitive Decline Hearing and vision loss can significantly impair cognitive testing performance and daily function, falsely suggesting dementia. Sensory deprivation increases cognitive load, social withdrawal, and misinterpretation of instructions¹⁵. Correction of hearing loss alone has been associated with improved cognitive trajectories. The Role of Objective Cognitive Testing. Conditions that Mimic Dementia Evaluating Memory Loss and Cognitive Decline: Delirium vs Dementia vs Reversible Causes Distinguishing dementia from its mimics requires more than brief screening tools or subjective impressions. Objective cognitive testing allows clinicians to: Quantify affected cognitive domains Identify patterns inconsistent with neurodegeneration Establish a reliable baseline Track change over time Assess response to intervention When integrated with careful history, medication review, laboratory evaluation, and appropriate imaging, objective testing is central to diagnostic accuracy. Clinical Takeaway A diagnosis of dementia should never be made lightly. Many conditions that mimic dementia are treatable, reversible, or modifiable , particularly when identified early. The physician’s task is not simply to name cognitive decline, but to determine why it is occurring . In many cases, that distinction preserves function, independence, and quality of life. Medical Reference Disclaimer This article is for educational purposes only and is not intended to diagnose or treat medical conditions. Individual evaluation by a qualified healthcare professional is essential. References Inouye SK, et al. Delirium in elderly people. Lancet . 2014. https://pubmed.ncbi.nlm.nih.gov/24488393/ Marcantonio ER. Delirium in hospitalized older adults. N Engl J Med . 2017. https://pubmed.ncbi.nlm.nih.gov/28953452/ Fong TG, et al. Delirium accelerates cognitive decline. Neurology . 2009. https://pubmed.ncbi.nlm.nih.gov/19433754/ Campbell NL, et al. Use of anticholinergics and cognitive impairment. Arch Intern Med . 2010. https://pubmed.ncbi.nlm.nih.gov/20585070/ Gray SL, et al. Cumulative anticholinergic use and dementia. JAMA Intern Med . 2015. https://pubmed.ncbi.nlm.nih.gov/25621434/ Alexopoulos GS. Depression and cognitive impairment. Lancet Psychiatry . 2019. https://pubmed.ncbi.nlm.nih.gov/31513714/ Rock PL, et al. Cognitive impairment in depression. Psychol Med . 2014. https://pubmed.ncbi.nlm.nih.gov/24799723/ Smith JW, et al. Hypothyroidism and cognition. Arch Intern Med . 2002. https://pubmed.ncbi.nlm.nih.gov/12437406/ O’Leary F, Samman S. Vitamin B12 and cognition. Nutrients . 2010. https://pubmed.ncbi.nlm.nih.gov/22254022/ Bellomo R, et al. Metabolic encephalopathy. Lancet . 2012. https://pubmed.ncbi.nlm.nih.gov/22632726/ Beebe DW, et al. Obstructive sleep apnea and cognition. Sleep . 2003. https://pubmed.ncbi.nlm.nih.gov/12683473/ Lim DC, Pack AI. CPAP and cognitive function. Chest . 2014. https://pubmed.ncbi.nlm.nih.gov/24189844/ Relkin N, et al. Diagnosing normal pressure hydrocephalus. Neurosurgery . 2005. https://pubmed.ncbi.nlm.nih.gov/16234659/ Graus F, et al. A clinical approach to autoimmune encephalitis. Lancet Neurol . 2016. https://pubmed.ncbi.nlm.nih.gov/26906964/ Livingston G, et al. Dementia prevention and sensory loss. Lancet . 2020. https://pubmed.ncbi.nlm.nih.gov/32738937/ Concerned about memory changes — for yourself or a loved one? Not all cognitive decline represents dementia. A comprehensive medical evaluation and objective cognitive testing can help distinguish neurodegenerative disease from treatable medical conditions. Schedule a cognitive consultation at Stages of Life Medical Institute  to ensure symptoms are accurately evaluated and addressed early. REFERENCES The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Uric acid has traditionally been viewed through a narrow clinical lens, largely confined to gout and nephrolithiasis. In recent years, however, it has become increasingly clear that uric acid functions as a broader metabolic and inflammatory signal , with relevance to cardiovascular disease, insulin resistance, and potentially cancer risk ¹⁻³. Among malignancies of interest, colorectal cancer  stands out. A growing body of epidemiologic and mechanistic data suggests that elevated serum uric acid may function as a predictive index , reflecting biological conditions that promote colorectal carcinogenesis years before clinical disease becomes apparent⁴⁻⁶. Uric Acid and Colorectal Cancer Risk What Is Uric Acid? Uric acid is the final metabolic product of purine degradation  in humans. Purines arise from endogenous cellular turnover and dietary sources such as red meat, organ meats, alcohol, and fructose-containing foods⁷. Under physiologic conditions, uric acid circulates in plasma and is excreted primarily by the kidneys. When production exceeds renal and intestinal excretion, serum levels rise. Biologically, uric acid plays a dual role : it functions as an extracellular antioxidant, yet once transported intracellularly, it promotes oxidative stress, mitochondrial dysfunction, and pro-inflammatory signaling ⁸⁻¹⁰. Uric Acid as a Marker of Metabolic Stress Elevated uric acid is strongly associated with: Insulin resistance Metabolic syndrome Central adiposity Hypertension Chronic low-grade inflammation¹¹⁻¹³ These same conditions are independently linked to increased colorectal cancer risk. Rather than acting as a single causative agent, uric acid likely reflects a metabolically permissive environment  characterized by oxidative stress, altered glucose metabolism, immune dysregulation, and impaired cellular repair mechanisms. Inflammation, Oxidative Stress, and Colorectal Carcinogenesis Chronic inflammation is a well-established driver of colorectal cancer. Elevated uric acid has been shown to: Activate NF-κB and inflammasome pathways Increase reactive oxygen species within epithelial cells Promote endothelial dysfunction and microvascular impairment Influence immune cell behavior within the tumor microenvironment¹⁴⁻¹⁶ Over time, these processes may facilitate DNA damage, impaired apoptosis, and dysregulated cellular proliferation within colonic tissue. Epidemiologic Evidence Linking Uric Acid and Colorectal Cancer Uric acid and colorectal cancer link Large observational cohorts have demonstrated a positive association between higher serum uric acid levels and colorectal cancer incidence , particularly in men and individuals with features of metabolic syndrome⁴⁻⁶,¹⁷. Notably, in several studies this association persisted after adjustment for age, BMI, smoking, diabetes, and renal function, suggesting uric acid may provide independent prognostic information  rather than acting solely as a confounder. Importantly, elevated uric acid often precedes diagnosis by many years, supporting its potential role as an early risk stratification marker  rather than a marker of established malignancy. The Role of Cologuard® in Average-Risk Screening Colorectal cancer screening and prevention overview For individuals at average risk  for colorectal cancer, stool-based screening with Cologuard® represents a validated, noninvasive screening option ¹⁸⁻²⁰. Cologuard combines fecal immunochemical testing (FIT) with molecular detection of altered DNA markers associated with colorectal neoplasia. While it does not replace colonoscopy, it has demonstrated high sensitivity for colorectal cancer and clinically meaningful sensitivity for advanced adenomas. In patients with metabolic risk factors or elevated inflammatory markers, Cologuard may improve screening adherence and serve as a practical entry point into guideline-based colorectal cancer prevention , with positive results appropriately followed by diagnostic colonoscopy. Clinical Implications for Preventive Medicine Uric acid offers several advantages as a clinical signal: Widely available and inexpensive Routinely measured Reflects modifiable metabolic processes Integrates nutrition, insulin signaling, renal handling, and inflammation Its greatest value lies in contextual interpretation , alongside insulin, triglycerides, hs-CRP, ferritin, waist circumference, and family history. What This Means for Patients An elevated uric acid level does not  diagnose colorectal cancer. It does suggest that metabolic and inflammatory conditions associated with increased cancer risk may be present. Addressing uric acid often overlaps with established colorectal cancer risk-reduction strategies: Improving insulin sensitivity Reducing fructose and ultra-processed foods Optimizing body composition Supporting gut health Reducing systemic inflammation In this way, uric acid becomes a preventive signal , prompting earlier intervention rather than delayed detection. A Measured Perspective Uric acid should not be viewed as a standalone cancer test. Its clinical relevance lies in pattern recognition over time , particularly when combined with other metabolic and inflammatory markers. As preventive medicine moves toward biology-driven risk assessment, uric acid may represent an underutilized, clinically accessible indicator  of colorectal cancer susceptibility—already present in routine laboratory data. REFERENCES Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med.  2008;359(17):1811-1821. https://pubmed.ncbi.nlm.nih.gov/18946066/ Johnson RJ, Nakagawa T, Sanchez-Lozada LG, et al. Sugar, uric acid, and the etiology of diabetes and obesity. Diabetes.  2013;62(10):3307-3315. https://pubmed.ncbi.nlm.nih.gov/24065788/ Borghi C, Rosei EA, Bardin T, et al. Serum uric acid and the risk of cardiovascular and renal disease. J Hypertens.  2015;33(9):1729-1741. https://pubmed.ncbi.nlm.nih.gov/26136212/ Strasak AM, Rapp K, Hilbe W, et al. Serum uric acid and risk of cancer mortality. Am J Epidemiol.  2007;166(5):651-657. https://pubmed.ncbi.nlm.nih.gov/17609496/ Lee J, Hong YS, Park SH, et al. Serum uric acid and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev.  2010;19(10):2471-2478. https://pubmed.ncbi.nlm.nih.gov/20826820/ You YN, Chen Z, Zhang C, et al. Hyperuricemia and colorectal cancer risk: A cohort study. BMC Cancer.  2021;21:1133. https://pubmed.ncbi.nlm.nih.gov/34736584/ Choi HK, Mount DB, Reginato AM. Pathogenesis of gout. Ann Intern Med.  2005;143(7):499-516. https://pubmed.ncbi.nlm.nih.gov/16204163/ Sautin YY, Johnson RJ. Uric acid: The oxidant-antioxidant paradox. Nucleosides Nucleotides Nucleic Acids.  2008;27(6):608-619. https://pubmed.ncbi.nlm.nih.gov/18600514/ Kanbay M, Segal M, Afsar B, et al. The role of uric acid in the pathogenesis of human cardiovascular disease. Heart.  2013;99(11):759-766. https://pubmed.ncbi.nlm.nih.gov/23349459/ Lanaspa MA, Sanchez-Lozada LG, Choi YJ, et al. Uric acid induces hepatic steatosis. J Biol Chem.  2012;287(48):40732-40744. https://pubmed.ncbi.nlm.nih.gov/23035112/ Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and metabolic syndrome. Circulation.  2007;115(19):2526-2532. https://pubmed.ncbi.nlm.nih.gov/17470699/ Nakagawa T, Tuttle KR, Short RA, Johnson RJ. Hypothesis: fructose-induced hyperuricemia as a causal mechanism. Kidney Int.  2005;68(2):642-650. https://pubmed.ncbi.nlm.nih.gov/16014044/ Kang DH, Park SK, Lee IK, Johnson RJ. Uric acid-induced C-reactive protein expression. Hypertension.  2005;46(4):932-937. https://pubmed.ncbi.nlm.nih.gov/16144982/ Martinon F, Petrilli V, Mayor A, et al. Gout-associated uric acid crystals activate the NLRP3 inflammasome. Nature.  2006;440(7081):237-241. https://pubmed.ncbi.nlm.nih.gov/16407889/ Zamarron BF, Chen W. Dual roles of uric acid in cancer. Clin Transl Oncol.  2021;23(6):1022-1032. https://pubmed.ncbi.nlm.nih.gov/33225333/ Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell.  2010;140(6):883-899. https://pubmed.ncbi.nlm.nih.gov/20303878/ Li J, Wang Y, Huang X, et al. Hyperuricemia and cancer incidence. Sci Rep.  2016;6:25655. https://pubmed.ncbi.nlm.nih.gov/27166916/ Imperiale TF, Ransohoff DF, Itzkowitz SH, et al. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med.  2014;370(14):1287-1297. https://pubmed.ncbi.nlm.nih.gov/24645800/ Redwood DG, Asay ED, Blake ID, et al. Stool DNA testing for colorectal cancer screening. Ann Intern Med.  2016;165(10):673-682. https://pubmed.ncbi.nlm.nih.gov/27618636/ Shaukat A, Kahi CJ, Burke CA, et al. ACG clinical guidelines: colorectal cancer screening. Am J Gastroenterol.  2021;116(3):458-479. https://pubmed.ncbi.nlm.nih.gov/33591341/ The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

Vitamins that are also Hormones Why That Changes How We Diagnose, Treat, and Think About It Below is a finished, physician-to-patient blog , aligned with your established template, tone, and educational depth. Vitamin D Is a Hormone — Not Just a Vitamin Most people think of vitamin D as a simple nutrient—something you take for bone health or to “boost immunity.” From a medical standpoint, that framing is incomplete and, at times, misleading. Vitamin D is not merely a vitamin. It functions as a steroid hormone , with widespread effects throughout the body. Understanding this distinction fundamentally changes how we evaluate deficiency, dosing, risk, and long-term health implications. Soy-Free Vitamin D3 in Olive Oil Why Vitamin D Breaks the Rules of Vitamins By definition, a vitamin is an essential nutrient that the body cannot manufacture in adequate amounts and must obtain from the diet. Vitamin D violates this definition in several important ways. The human body: Synthesizes vitamin D in the skin  in response to ultraviolet B (UVB) radiation Converts it through a two-step endocrine activation process Uses the active form to regulate gene expression These characteristics place vitamin D squarely in the category of hormones , not traditional vitamins. The Hormonal Activation Pathway Vitamin D undergoes a tightly regulated process similar to other steroid hormones: Skin:  UVB exposure converts 7-dehydrocholesterol into cholecalciferol (vitamin D₃) Liver:  Conversion to 25-hydroxyvitamin D [25(OH)D], the storage form measured in blood tests Kidney (and other tissues):  Conversion to 1,25-dihydroxyvitamin D (calcitriol), the active hormone Calcitriol binds to the vitamin D receptor (VDR) , a nuclear receptor found in over 30 different tissues , influencing the transcription of hundreds of genes. Vitamin D Receptors: Everywhere That Matters Differences between Vitamins and Minerals Vitamin D receptors are found far beyond bone and calcium pathways, including: Brain and central nervous system Immune cells (T cells, B cells, macrophages) Cardiovascular tissue Skeletal muscle Pancreatic beta cells Colon, breast, and prostate tissue This widespread receptor distribution explains why vitamin D status has been linked to outcomes far beyond osteoporosis. For Osteoporosis or Osteopenia, take Vitamin D3 with Vitamin K2 Clinical Roles of Vitamin D as a Hormone Bone and Mineral Metabolism Vitamin D regulates: Intestinal calcium and phosphorus absorption Bone remodeling Parathyroid hormone (PTH) suppression Deficiency leads not only to osteopenia and osteoporosis, but also increased fracture risk and impaired bone quality. Immune Modulation Vitamin D: Enhances innate immune defense Modulates inflammatory cytokine production Helps regulate autoimmune responses Low levels have been associated with increased susceptibility to respiratory infections and dysregulated immune activity. Muscle Function and Falls Adequate vitamin D levels support: Muscle strength Neuromuscular coordination Reduced fall risk in older adults Muscle weakness is often one of the earliest—and least recognized—signs of deficiency. Brain and Cognitive Health Vitamin D plays a role in: Neuroprotection Neurotransmitter regulation Reduction of neuroinflammation Emerging evidence links low vitamin D levels to cognitive decline and increased dementia risk, particularly in aging populations. Why Deficiency Is So Common Despite its importance, vitamin D deficiency is widespread—even in sunny climates. Contributing factors include: Limited sun exposure Sunscreen use and indoor lifestyles Aging skin (reduced synthesis) Obesity (vitamin D sequestration in fat tissue) Malabsorption syndromes Chronic kidney or liver disease Diet alone is rarely sufficient to maintain optimal levels. What Blood Levels Really Mean The standard test, 25-hydroxyvitamin D , reflects body stores—not active hormone levels. From a clinical perspective: Levels below 20 ng/mL indicate deficiency 20–30 ng/mL is often insufficient Many physicians aim for 30–50 ng/mL  to support broader physiologic functions Optimal targets may vary based on age, bone health, immune status, and comorbid disease. Why Dosing Requires Medical Judgment Because vitamin D is fat-soluble and hormonally active: Excessive dosing can lead to toxicity Calcium balance must be monitored Individual response varies widely Supplementation should be intentional, monitored, and personalized , not arbitrary. The Takeaway Calling vitamin D “just a vitamin” understates its importance and invites under-treatment. In reality, vitamin D functions as a master regulatory hormone  influencing bone, immune, muscle, and brain health. Recognizing this distinction allows patients and clinicians to move beyond casual supplementation toward evidence-based assessment, targeted dosing, and meaningful prevention . In upcoming posts, we’ll explore how vitamin D interacts with calcium, magnesium, hormones, and inflammation , and why balance—not megadosing—is the key to long-term health. References Holick MF.  Vitamin D deficiency. N Engl J Med.  2007;357(3):266–281. https://pubmed.ncbi.nlm.nih.gov/17634462/ DeLuca HF.  Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr.  2004;80(6 Suppl):1689S–1696S. https://pubmed.ncbi.nlm.nih.gov/15585789/ Christakos S, et al.  Vitamin D: metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev.  2016;96(1):365–408. https://pubmed.ncbi.nlm.nih.gov/26681795/ Norman AW.  From vitamin D to hormone D: fundamentals of the vitamin D endocrine system. Am J Clin Nutr.  2008;88(2):491S–499S. https://pubmed.ncbi.nlm.nih.gov/18689389/ Bikle DD.  Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol.  2014;21(3):319–329. https://pubmed.ncbi.nlm.nih.gov/24529992/ Haussler MR, et al.  The nuclear vitamin D receptor: biological and molecular regulatory properties. J Bone Miner Res.  1998;13(3):325–349. https://pubmed.ncbi.nlm.nih.gov/9525333/ Bouillon R, et al.  Vitamin D and human health: lessons from vitamin D receptor null mice. Endocr Rev.  2008;29(6):726–776. https://pubmed.ncbi.nlm.nih.gov/18694980/ Prietl B, et al.  Vitamin D and immune function. Nutrients.  2013;5(7):2502–2521. https://pubmed.ncbi.nlm.nih.gov/23857223/ Aranow C.  Vitamin D and the immune system. J Investig Med.  2011;59(6):881–886. https://pubmed.ncbi.nlm.nih.gov/21527855/ Bischoff-Ferrari HA, et al.  Effect of vitamin D on falls: a meta-analysis. JAMA.  2004;291(16):1999–2006. https://pubmed.ncbi.nlm.nih.gov/15113819/ Wang Y, et al.  Vitamin D and risk of cardiovascular disease. Circulation.  2008;117(4):503–511. https://pubmed.ncbi.nlm.nih.gov/18180395/ Annweiler C, et al.  Vitamin D and cognition in older adults: updated systematic review. J Intern Med.  2013;273(6):509–522. https://pubmed.ncbi.nlm.nih.gov/23489360/ Eyles DW, et al.  Vitamin D and brain development. Neuroscience.  2013;118(3):641–653. https://pubmed.ncbi.nlm.nih.gov/12699736/ Pilz S, et al.  Vitamin D and mortality risk: a meta-analysis. Am J Clin Nutr.  2009;89(3):713–724. https://pubmed.ncbi.nlm.nih.gov/19116333/ Rosen CJ, et al.  The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev.  2012;33(3):456–492. https://pubmed.ncbi.nlm.nih.gov/22596255/ Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

St. John’s wort is often perceived as a gentle, plant-based option for mood support. Because it is sold over the counter and labeled as “natural,” many patients assume it is inherently safe. From a physician’s perspective, that assumption is not only incorrect—it can be dangerous . St. John’s wort is one of the most clinically significant drug-interacting supplements in widespread use today , capable of reducing the effectiveness of numerous prescription medications, sometimes with serious or life-threatening consequences.¹⁻³ St. John's Wort can cause drug interactions What Is St. John’s Wort? St. John’s wort ( Hypericum perforatum ) is an herbal preparation traditionally used for mild to moderate depression, anxiety, and mood symptoms. Its primary active constituents include hyperforin  and hypericin , compounds that exert effects on neurotransmitters such as serotonin, dopamine, and norepinephrine.¹,² While these properties explain its antidepressant effects, they also underpin its high risk for drug interactions . The Core Problem: Potent Enzyme Induction St. John’s wort is a strong inducer of hepatic and intestinal drug-metabolizing enzymes , particularly: Cytochrome P450 3A4 (CYP3A4) Cytochrome P450 2C9 and 2C19 P-glycoprotein (P-gp) transporters These systems are responsible for the metabolism and transport of a large proportion of commonly prescribed medications. When St. John’s wort induces these pathways, it accelerates drug clearance , often lowering blood levels below therapeutic thresholds.³⁻⁵ Importantly, this effect is not subtle—it can be profound. Tell your physician or Surgeon if you are taking this supplement. It can save your life. Medications Commonly Affected Antidepressants and Psychiatric Medications Combining St. John’s wort with SSRIs, SNRIs, tricyclic antidepressants, or other serotonergic agents increases the risk of serotonin syndrome , a potentially life-threatening condition characterized by agitation, hyperthermia, tremor, and autonomic instability.⁶⁻⁸ This interaction is especially concerning because patients often self-add St. John’s wort without informing their clinician . Oral Contraceptives St. John’s wort can significantly reduce estrogen and progestin levels, leading to contraceptive failure and unintended pregnancy .⁹⁻¹¹ Multiple case reports and pharmacokinetic studies have documented breakthrough bleeding and ovulation in women taking oral contraceptives alongside St. John’s wort.¹⁰,¹¹ Anticoagulants and Cardiovascular Drugs St. John’s wort reduces plasma concentrations of: Warfarin Direct oral anticoagulants Certain antiarrhythmics This interaction increases the risk of thromboembolic events , including stroke and pulmonary embolism.¹²,¹³ In patients with atrial fibrillation, prosthetic valves, or prior clotting events, this risk is particularly dangerous. Transplant and Immunosuppressive Medications Perhaps the most alarming interactions involve immunosuppressive agents , including cyclosporine and tacrolimus. St. John’s wort has been shown to precipitate acute transplant rejection  by lowering drug levels below therapeutic ranges.¹⁴,¹⁵ These interactions are well documented and widely cited in transplant medicine. Why These Interactions Are Often Missed Several factors contribute to under-recognition: Patients do not consider supplements to be “medications” Clinicians may not routinely ask about herbal products Effects may appear weeks after initiation Drug levels decline silently before clinical failure occurs This makes St. John’s wort uniquely hazardous—it often causes harm without immediate warning signs . “Natural” Does Not Mean Safe From a pharmacologic standpoint, St. John’s wort behaves more like a broad-spectrum enzyme-inducing drug  than a benign supplement. Its effects are: Dose dependent Sustained over time Clinically unpredictable between individuals Unlike prescription medications, there is no standardized dosing, formulation, or monitoring . Who Should Avoid St. John’s Wort Entirely? St. John’s wort should generally be avoided in patients who : Take prescription antidepressants Use hormonal contraception Take anticoagulants or cardiac medications Are transplant recipients Take seizure medications Are on complex or multiple drug regimens In these populations, the risks consistently outweigh any potential benefit.³⁻⁶,¹²⁻¹⁵ The Takeaway: St. John's Wort can be dangerous St. John’s wort is not a harmless herbal remedy. It is a potent modulator of drug metabolism  with the ability to reduce medication effectiveness, trigger dangerous interactions, and cause serious clinical harm. From a physician’s perspective, the most important message is this: Any supplement capable of altering liver enzymes must be treated like a prescription drug. Patients should never start St. John’s wort without discussing it with a qualified clinician—especially if they take prescription medications. Transparency, careful review, and medical oversight are essential to avoid preventable and potentially life-threatening outcomes. Taking Supplements Alongside Prescription Medications? Many “natural” products can interfere with critical drug therapies. At Stages of Life Medical Institute , we perform comprehensive medication and supplement reviews to identify hidden risks and prevent dangerous interactions. 👉 Schedule a medication and supplement safety review today. The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. References: Barnes J, et al. St John’s wort (Hypericum perforatum): a review of its chemistry, pharmacology and clinical properties.  J Pharm Pharmacol. 2001. https://pubmed.ncbi.nlm.nih.gov/11428685/ Linde K, et al. St John’s wort for depression—an overview and meta-analysis.  BMJ. 2008. https://pubmed.ncbi.nlm.nih.gov/18669545/ Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs.  Drugs. 2009. https://pubmed.ncbi.nlm.nih.gov/19453202/ Markowitz JS, et al. Effect of St John’s wort on cytochrome P450 enzymes.  Clin Pharmacol Ther. 2003. https://pubmed.ncbi.nlm.nih.gov/12576308/ Dresser GK, et al. Induction of P-glycoprotein by St John’s wort.  Clin Pharmacol Ther. 2003. https://pubmed.ncbi.nlm.nih.gov/12966369/ Mills E, et al. Herb–drug interactions: review.  Lancet. 2005. https://pubmed.ncbi.nlm.nih.gov/16023513/ Izzo AA. Herb–drug interactions with St John’s wort.  Drug Saf. 2004. https://pubmed.ncbi.nlm.nih.gov/15053437/ Boyer EW, Shannon M. The serotonin syndrome.  N Engl J Med. 2005. https://pubmed.ncbi.nlm.nih.gov/16079372/ Murphy PA, et al. St John’s wort and oral contraceptive failure.  Contraception. 2005. https://pubmed.ncbi.nlm.nih.gov/16022849/ Hall SD, et al. The interaction between St John’s wort and oral contraceptives.  Clin Pharmacol Ther. 2003. https://pubmed.ncbi.nlm.nih.gov/12891224/ Schwarz UI, et al. St John’s wort induces CYP3A4 and reduces contraceptive efficacy.  Clin Pharmacol Ther. 2003. https://pubmed.ncbi.nlm.nih.gov/12709724/ Jiang X, et al. Effect of St John’s wort on warfarin anticoagulation.  Br J Clin Pharmacol. 2004. https://pubmed.ncbi.nlm.nih.gov/15151530/ Piscitelli SC, et al. Induction of cytochrome P450 by St John’s wort.  Clin Infect Dis. 2000. https://pubmed.ncbi.nlm.nih.gov/10981743/ Ruschitzka F, et al. Acute heart transplant rejection due to St John’s wort.  Lancet. 2000. https://pubmed.ncbi.nlm.nih.gov/10920459/ Mai I, et al. Dangerous interaction between St John’s wort and cyclosporine.  Br J Clin Pharmacol. 2000. https://pubmed.ncbi.nlm.nih.gov/10930955/ Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

A Silent Driver of Atherosclerotic Cardiovascular Disease Introduction If you are truly interested in a healthy diet, if you are truly interested in learning the why and how of nutrition and nutritional medicine, this is article is an important investment of your valuable time. While it seems like a very dry, academic topic, it is likely to change your behavior in a meaningful and healthy way. Please share this one with your friends and family, it may change them, for the better, as well. Background Atherosclerotic cardiovascular disease (ASCVD) is often framed as a problem of cholesterol alone. While lipoproteins remain central, this view is incomplete. A growing body of evidence points to advanced glycation end products (AGEs)  as a powerful, under-recognized contributor to vascular aging, endothelial dysfunction, inflammation, and plaque instability. AGEs accumulate slowly and quietly over decades. By the time ASCVD becomes clinically evident, the biological damage has often been underway for years. Understanding AGEs changes how we think about cardiovascular risk, prevention, and longevity. What Are Advanced Glycation End Products? Advanced glycation end products causing cardiovascular disease, diabetes, kidney disease, neurodegeneration, and eye damage AGEs are harmful compounds formed when sugars react non-enzymatically with proteins, lipids, or nucleic acids, a process known as the Maillard reaction . This reaction accelerates under conditions common in modern life: Chronic hyperglycemia Insulin resistance and diabetes Oxidative stress High-temperature food preparation (grilling, frying, roasting) Once formed, AGEs are biologically persistent. They accumulate in long-lived tissues such as vascular collagen, myocardium, kidney, retina, and neural tissue¹². Endogenous vs Exogenous AGEs Endogenous AGEs Produced within the body as a consequence of: Elevated glucose exposure Mitochondrial oxidative stress Aging-related metabolic inefficiency Exogenous AGEs Absorbed directly from food, particularly: Charred meats Fried foods Baked and roasted products Ultra-processed foods Dietary AGEs significantly raise circulating AGE burden and inflammatory markers, independent of calories or macronutrient composition³⁴. How AGEs Promote ASCVD How Advanced Glycation End Products Form AGEs contribute to atherosclerosis through multiple converging mechanisms : 1. Endothelial Dysfunction AGEs cross-link collagen within the arterial wall, increasing stiffness and impairing nitric oxide signaling. The result is reduced vasodilation and increased shear stress⁵⁶. 2. Chronic Inflammation via RAGE AGE RAGE Pathway and Vascular Damage AGEs bind to the Receptor for Advanced Glycation End Products (RAGE) , activating NF-κB and sustaining low-grade vascular inflammation. This signaling loop perpetuates oxidative stress and cytokine production⁷⁸. 3. LDL Modification and Foam Cell Formation Glycated LDL is more readily oxidized and less efficiently cleared, promoting macrophage uptake and foam cell formation, a hallmark of early plaque development⁹. 4. Plaque Instability AGE accumulation weakens fibrous caps and promotes metalloproteinase activity, increasing the risk of plaque rupture and thrombosis¹⁰. AGEs, Diabetes, and “Residual Risk” Even in well-controlled diabetes, AGEs persist due to prior glycemic exposure, a phenomenon known as metabolic memory ¹¹. This explains why cardiovascular risk often remains elevated despite improved A1c levels. Importantly, AGE burden also rises in non-diabetic individuals  with insulin resistance, visceral adiposity, and sedentary lifestyles, making this a broader cardiometabolic issue¹². Clinical Markers and Assessment While AGEs are not yet part of routine cardiovascular screening, several surrogate indicators raise suspicion for elevated AGE burden: Elevated fasting insulin Increased HbA1c within “normal” range Oxidative stress markers Vascular stiffness (pulse wave velocity) Skin autofluorescence (research and select clinical settings)¹³ Reducing AGE Burden: Practical Strategies Nutrition Favor steaming, boiling, poaching over grilling or frying Emphasize whole, unprocessed foods Reduce refined carbohydrates and fructose exposure Glycemic Control Optimize insulin sensitivity Address post-prandial glucose excursions Antioxidant and Nutrient Support N-acetylcysteine (NAC) Alpha-lipoic acid Vitamin C and E Polyphenols (curcumin, resveratrol)¹⁴ Lifestyle Regular aerobic and resistance exercise Weight optimization Sleep and stress regulation What you can do, right now: Dietary Sources of Advanced Glycation End Products Control your sugar intake: Limit refined sugars, soft drinks, alcohol Modify cooking: Boil and steaming food is healthier than baking, frying and grilling (particularly over open flame) Eat whole (unprocessed) foods: A good start is the Mediterranean diet. These interventions reduce AGE formation, enhance clearance, and blunt RAGE-mediated inflammation¹⁵. Why This Matters Clinically AGEs provide a unifying mechanism  linking aging, diabetes, oxidative stress, and ASCVD. Addressing them shifts cardiovascular care from reaction to prevention and reframes risk assessment beyond cholesterol alone. For patients focused on longevity, vascular health, and cognitive preservation, AGE reduction represents a meaningful and actionable target. REFERENCES Brownlee M.  Biochemistry and molecular cell biology of diabetic complications. Nature . 2001;414(6865):813–820. https://pubmed.ncbi.nlm.nih.gov/11742414/ Singh R, et al.  Advanced glycation end-products: a review. Diabetologia . 2001;44(2):129–146. https://pubmed.ncbi.nlm.nih.gov/11270668/ Uribarri J, et al.  Dietary advanced glycation end products and their role in health and disease. Adv Nutr . 2015;6(4):461–473. https://pubmed.ncbi.nlm.nih.gov/26178075/ Vlassara H, et al.  Dietary glycotoxins. Proc Natl Acad Sci U S A . 2002;99(24):15596–15601. https://pubmed.ncbi.nlm.nih.gov/12429856/ Semba RD, et al.  Advanced glycation end products and arterial stiffness. J Gerontol A Biol Sci Med Sci . 2009;64A(7):742–748. https://pubmed.ncbi.nlm.nih.gov/19359445/ Goldin A, et al.  Advanced glycation end products: sparking the development of diabetic vascular injury. Circulation . 2006;114(6):597–605. https://pubmed.ncbi.nlm.nih.gov/16894049/ Ramasamy R, et al.  Receptor for advanced glycation end products and inflammation. J Clin Invest . 2009;119(10):2523–2532. https://pubmed.ncbi.nlm.nih.gov/19729818/ Schmidt AM, et al.  RAGE signaling in vascular disease. Arterioscler Thromb Vasc Biol . 2010;30(8):1509–1517. https://pubmed.ncbi.nlm.nih.gov/20595672/ Bucala R, et al.  Modification of LDL by advanced glycation end products. Proc Natl Acad Sci U S A . 1994;91(20):9441–9445. https://pubmed.ncbi.nlm.nih.gov/7937785/ Basta G, et al.  Advanced glycation end products activate endothelial cells. Cardiovasc Res . 2004;63(2):267–275. https://pubmed.ncbi.nlm.nih.gov/15249186/ Ceriello A.  The concept of metabolic memory. Diabetes Care . 2009;32(Suppl 2):S245–S250. https://pubmed.ncbi.nlm.nih.gov/19875544/ Baynes JW.  Role of oxidative stress in development of complications in diabetes. Free Radic Biol Med . 2001;31(9):1157–1170. https://pubmed.ncbi.nlm.nih.gov/11677047/ Meerwaldt R, et al.  Skin autofluorescence as a measure of AGE accumulation. Diabetes Care . 2004;27(10):2246–2251. https://pubmed.ncbi.nlm.nih.gov/15451899/ Ziegler D, et al.  Alpha-lipoic acid in the treatment of diabetic neuropathy. Diabetes Care . 1999;22(8):1296–1301. https://pubmed.ncbi.nlm.nih.gov/10480775/ Uribarri J, et al.  Restriction of dietary advanced glycation end products improves insulin resistance. Diabetes Care . 2011;34(7):1610–1616. https://pubmed.ncbi.nlm.nih.gov/21617107/ The medical references cited in this article are provided for educational purposes only and are intended to support general scientific discussion. They are not a substitute for individualized medical advice, diagnosis, or treatment. Clinical decisions should always be made in consultation with a qualified healthcare professional who can account for a patient’s unique medical history, medications, and circumstances. Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

A Familiar but Important Pattern Seasonal Influenza Outbreaks are Predictable Each winter, influenza follows a somewhat predictable epidemiologic pattern. This season has been no exception. Influenza A  emerged early and aggressively, driving the initial surge in hospitalizations, urgent care visits, and missed work and school¹². More recently, Influenza B  has begun to circulate more widely, prolonging the overall flu season and catching many patients off guard³⁴. Understanding the differences between these two strains helps explain why flu symptoms may persist in the community even after the initial wave appears to subside. Influenza A: The Early and More Severe Wave Influenza A viruses are responsible for most seasonal epidemics and pandemics . They mutate rapidly and are often associated with more severe disease , particularly in older adults, young children, and those with chronic medical conditions⁵⁶. This season’s Influenza A outbreak was characterized by: High early transmission rates Increased emergency department utilization Significant systemic symptoms (high fever, myalgias, profound fatigue)¹⁷ Influenza A is also more likely to cause complications , including pneumonia, cardiac stress, and worsening of underlying pulmonary disease⁸⁹. Influenza B: The Later, Lingering Threat As Influenza A activity begins to decline, Influenza B often rises , particularly later in the flu season³¹⁰. While sometimes perceived as “milder,” Influenza B can still cause significant illness , especially in children, adolescents, and older adults¹¹¹². Notably: Influenza B circulates almost exclusively in humans It tends to spread later in the season It can prolong community-wide illness even when people believe “flu season is over”⁴¹³ Patients may assume they have a new respiratory virus or a “bad cold,” when in fact they are experiencing a second, distinct influenza infection . Why This Matters Clinically From a physician’s perspective, the sequential appearance of Influenza A followed by Influenza B explains why: Flu activity seems prolonged Patients may become ill twice in one season Ongoing vigilance remains necessary even late in winter¹⁴ Vaccination, early testing, and timely antiviral treatment remain essential tools, particularly for high-risk individuals¹⁵. Practical Takeaways for Patients Influenza A typically strikes earlier and harder Influenza B often extends the season Fever, body aches, cough, and fatigue should still prompt evaluation Antiviral treatment is most effective when started early Preventive measures remain important even late in the season Influenza is not a single event—it is a dynamic, evolving outbreak  that unfolds in phases. Summary This year’s influenza season has followed a classic but clinically important pattern: an early Influenza A surge followed by a later Influenza B wave . Recognizing this progression helps patients understand why flu activity persists and why ongoing awareness, testing, and prevention remain critical well beyond the initial outbreak. References Iuliano AD, et al. Estimates of global seasonal influenza-associated respiratory mortality. Lancet.  2018;391(10127):1285–1300. https://pubmed.ncbi.nlm.nih.gov/29248255/ Centers for Disease Control and Prevention. Disease burden of influenza. CDC.   https://pubmed.ncbi.nlm.nih.gov/30285306/ Caini S, et al. Characteristics of seasonal influenza B epidemics. PLoS One.  2015;10(3):e0120175. https://pubmed.ncbi.nlm.nih.gov/25760637/ Paul Glezen W, et al. Influenza B virus circulation patterns. J Infect Dis.  2013;208(2):271–279. https://pubmed.ncbi.nlm.nih.gov/23570866/ Taubenberger JK, Morens DM. Influenza viruses: pathogenesis and host response. Annu Rev Pathol.  2008;3:499–522. https://pubmed.ncbi.nlm.nih.gov/18233933/ Webster RG, et al. Evolution and ecology of influenza A viruses. Microbiol Rev.  1992;56(1):152–179. https://pubmed.ncbi.nlm.nih.gov/1579108/ Monto AS, et al. Medical practice burden of influenza. Clin Infect Dis.  2004;38(4):483–491. https://pubmed.ncbi.nlm.nih.gov/14765342/ Madjid M, et al. Influenza and cardiovascular disease. J Am Coll Cardiol.  2004;44(5):1178–1182. https://pubmed.ncbi.nlm.nih.gov/15337215/ Jain S, et al. Hospitalized patients with 2009 H1N1 influenza. N Engl J Med.  2009;361(20):1935–1944. https://pubmed.ncbi.nlm.nih.gov/19815859/ Heikkinen T, et al. Influenza B in children. Pediatr Infect Dis J.  2004;23(7):674–679. https://pubmed.ncbi.nlm.nih.gov/15247640/ Tran D, et al. Hospitalization burden of influenza B. Clin Infect Dis.  2016;63(12):1525–1532. https://pubmed.ncbi.nlm.nih.gov/27578820/ Chiu SS, et al. Influenza B severity in children. Clin Infect Dis.  2002;35(6):669–679. https://pubmed.ncbi.nlm.nih.gov/12203164/ Ambrose CS, Levin MJ. The rationale for quadrivalent influenza vaccines. Hum Vaccin Immunother.  2012;8(1):81–88. https://pubmed.ncbi.nlm.nih.gov/22252006/ Uyeki TM, et al. Clinical practice guidelines for influenza. Clin Infect Dis.  2019;68(6):e1–e47. https://pubmed.ncbi.nlm.nih.gov/30834477/ Jefferson T, et al. Neuraminidase inhibitors for influenza. Cochrane Database Syst Rev.  2014;4:CD008965. https://pubmed.ncbi.nlm.nih.gov/24718923/ Subscribe to our Blog   Highest Quality, GMP Manufactured Products 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com

A physician’s guide for patients—clear, evidence-based, and practical. Most people take vitamins, yet surprisingly few understand what a vitamin actually is. The term is often used loosely to describe anything sold in a supplement aisle, but in medicine and biology, vitamins have a precise definition . Understanding that definition—and where important exceptions exist—helps patients make better decisions about nutrition, supplementation, and long-term health. A clear definition A vitamin  is an organic compound  required in small amounts  for normal metabolism, cellular function, growth, and repair— and one that the human body cannot synthesize in adequate quantities on its own . This definition matters. If the body can make enough of a substance, it is not  a vitamin. If the substance is inorganic (such as calcium or iron), it is a mineral , not a vitamin . Vitamins occupy a narrow but essential biological category. The two major vitamin families Vitamins are traditionally classified by how they are absorbed, transported, and stored. Fat-soluble vitamins Fat-soluble vitamins dissolve in dietary fat, are absorbed through the intestinal lymphatic system, and can be stored in body tissues , particularly the liver and adipose tissue. They include: Vitamin A Vitamin D Vitamin E Vitamin K Because they are stored, deficiencies usually develop slowly—but excessive intake can accumulate and cause toxicity . An important exception: vitamin D Although vitamin D is traditionally grouped with fat-soluble vitamins, it functions biologically as a hormone, not a true vitamin . Unlike other vitamins, vitamin D can be synthesized by the human body  when ultraviolet B (UVB) sunlight interacts with cholesterol in the skin. It is then activated in the liver and kidneys to form calcitriol , a steroid (secosteroid) hormone that binds to nuclear receptors and directly regulates gene expression . Vitamin D receptors are found throughout the body, including bone, muscle, immune cells, the cardiovascular system, and the brain. This explains why vitamin D affects bone health, immune regulation, inflammation, insulin sensitivity, neuromuscular function, and more. It remains labeled a “vitamin” largely for historical reasons, because deficiency was first recognized through dietary disease (rickets). Clinically, it is more accurate to think of vitamin D as a hormone with vitamin-like deficiency states , which is why blood testing and individualized dosing are often appropriate. Water-soluble vitamins Water-soluble vitamins dissolve in water, circulate freely in the bloodstream, and excess amounts are usually excreted in urine. They include: Vitamin C B-complex vitamins (B1, B2, B3, B5, B6, B7, B9, B12) Because they are not extensively stored, deficiencies can develop more quickly, particularly with poor intake, malabsorption, medication effects, or increased metabolic demand. Vitamins vs hormones: a simple comparison Many patients are surprised to learn that vitamin D behaves more like a hormone than a vitamin. The distinction is helpful. In simple terms: Vitamins  must come primarily from the diet and act mainly as enzyme cofactors. Hormones  are produced in the body, circulate as signaling molecules, and regulate gene expression and organ function. Vitamin D sits at the intersection of these categories. What vitamins actually do Vitamins do not  provide energy or calories. Instead, they enable the chemical reactions that allow cells to function. They commonly act as: Enzyme cofactors Regulators of cellular metabolism Antioxidants Facilitators of neurotransmitter and hormone synthesis Without adequate vitamin availability, metabolic pathways slow or malfunction—even when calories are plentiful. Why deficiencies still occur Vitamin deficiency is not confined to poverty or famine. Subclinical deficiency is common, especially in older adults. Common contributors include: Highly processed diets Reduced appetite or restrictive eating Gastrointestinal disorders or surgery Certain medications (e.g., metformin, proton-pump inhibitors) Reduced sun exposure Increased needs with aging, illness, or stress Symptoms are often subtle at first—fatigue, neuropathy, cognitive slowing, immune vulnerability, or bone loss. Food first—usually Whole foods remain the preferred source of vitamins because they provide supportive nutrients that enhance absorption and utilization. Examples include: Leafy greens → folate, vitamin K Fatty fish → vitamin D, vitamin A Citrus and vegetables → vitamin C Eggs and meats → B12, biotin However, food alone does not always meet needs. Great value in GMP quality Vitamins & Minerals for less than $26 per month When supplementation is appropriate Supplementation is often reasonable when: A deficiency is documented Absorption is impaired Dietary intake is consistently inadequate Requirements increase with age or illness Evidence supports benefit in deficient individuals The goal is targeted supplementation , not indiscriminate use. More is not better Excess intake—particularly of fat-soluble vitamins—can cause harm. The objective is physiologic adequacy , not maximal dosing. Bottom line A vitamin is not a marketing term or wellness trend. It is a biologically essential compound required for normal human physiology. Vitamin D stands apart as a hormone that behaves like a vitamin only in deficiency. Understanding these distinctions empowers patients to approach nutrition and supplementation with clarity, realism, and safety—ideally guided by medical evidence and individualized care. References Combs GF. The Vitamins: Fundamental Aspects in Nutrition and Health.  Elsevier; 2012. Ames BN. Low micronutrient intake may accelerate aging. Proc Natl Acad Sci USA.  2006;103(47):17589-17594. https://pubmed.ncbi.nlm.nih.gov/17101960/ Holick MF. Vitamin D deficiency. N Engl J Med.  2007;357:266-281. https://pubmed.ncbi.nlm.nih.gov/17634462/ Christakos S, et al. Vitamin D metabolism, molecular mechanism of action, and pleiotropic effects. Physiol Rev.  2016;96(1):365-408. https://pubmed.ncbi.nlm.nih.gov/26681795/ O’Leary F, Samman S. Vitamin B12 in health and disease. Nutrients.  2010;2(3):299-316. https://pubmed.ncbi.nlm.nih.gov/22254022/ Troesch B, et al. Increased micronutrient needs with aging. Clin Interv Aging.  2012;7:231-245. https://pubmed.ncbi.nlm.nih.gov/22888231/ NIH Office of Dietary Supplements. Vitamins and Minerals Fact Sheets. https://pubmed.ncbi.nlm.nih.gov/ Schleicher RL, et al. Trends in vitamin status in the U.S. population. Am J Clin Nutr.  2016;103(1):274-284. https://pubmed.ncbi.nlm.nih.gov/26702154/ EFSA Panel. Tolerable upper intake levels for vitamins. EFSA J.  2018. https://pubmed.ncbi.nlm.nih.gov/ Institute of Medicine. Dietary Reference Intakes for Vitamins.  National Academies Press; 2011. Subscribe to our Blog   Sponsored by Stages of Life Vitamins 1917 Boothe Circle, Suite 171 Longwood, Florida 32750 Tel: 407-679-3337 Fax: 407-678-7246 www.suffernomore.com